TABLE 2.
Representative differential metabolites in liver of control, model and CuB group.
| No. | RT | Metabolite | Formula | MW | HMDB ID | ESI mode | MS/MS fragments | Change trend | |
|---|---|---|---|---|---|---|---|---|---|
| a | b | ||||||||
| 1 | 2.49 | Pipecolic acid | C6H11NO2 | 129.0787 | HMDB0000070 | + | [130.0863] [102.0555] | ↑ | ↑ |
| 2 | 3.02 | L-Methionine | C5H11NO2S | 149.0507 | HMDB0000696 | + | [150.0585] [133.0316] [102.0550] | ↓ | ↑ |
| 3 | 3.18 | 3-Hydroxybutyrylcarnitine | C11H21NO5 | 247.1419 | HMDB0013127 | + | [248.1486] [189.0754] | ↑ | - |
| 4 | 3.21 | Phenylpyruvic acid | C9H8O3 | 164.0464 | HMDB0000205 | + | [165.0541] [119.0486] [103.0540] | ↓ | ↑ |
| 5 | 3.22 | L-Tyrosine | C9H11NO3 | 181.0739 | HMDB0000158 | + | [182.0811] [147.0435] [123.0445] | ↓ | ↑ |
| 6 | 3.33 | Hypoxanthine | C5H4N4O | 136.0383 | HMDB0000157 | + | [137.0458] [119.0338] [110.0344] | ↓ | ↑ |
| 7 | 5.11 | S-Acetyldihydrolipoamide-E | C10H19NO2S2 | 249.0859 | HMDB0006878 | + | [250.0933] [232.0805] [190.0699] | ↓ | ↑ |
| 8 | 5.77 | Pantetheine 4′-phosphate | C11H23N2O7PS | 358.0955 | HMDB0001416 | − | [357.0891] [226.0488] [181.0276] | ↓ | ↑ |
| 9 | 8.50 | Glutamylarginine | C11H21N5O5 | 303.1678 | HMDB0028813 | + | [304.1747] [245.1005] [227.0898] | ↓ | ↑ |
| 10 | 22.41 | Sphingosine | C18H37NO2 | 299.2822 | HMDB0000252 | + | [300.2895] [282.2785] [264.2673] | ↑ | ↓ |
| 11 | 23.66 | LysoPE(18:2(9Z,12Z)/0:0) | C23H44NO7P | 477.2846 | HMDB0011507 | + | [478.2925] [337.2745] [263.2325] | ↓ | - |
| 12 | 23.76 | LysoPE(20:4(8Z,11Z,14Z,17Z)/0:0) | C25H44NO7P | 501.2852 | HMDB0011518 | + | [502.2931] [363.2836] [361.2732] | ↓ | ↓ |
| 13 | 27.98 | N-Nervonoyl Serine | C27H51NO4 | 453.3811 | HMDB0242099 | + | [454.3890] [123.1165] [109.1003 | ↑ | ↓ |
RT, retention time; a, control group vs. formative stage of HCC; b, formative stage of HCC vs. CuB group; “↑” mean up; “↓” mean down; “-” mean not detected.